These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 18710447)

  • 1. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
    Boormans JL; Wildhagen MF; Bangma CH; Verhagen PC; van Leenders GJ
    BJU Int; 2008 Dec; 102(11):1589-93. PubMed ID: 18710447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
    Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
    Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases.
    Fleischmann A; Schobinger S; Schumacher M; Thalmann GN; Studer UE
    Prostate; 2009 Mar; 69(4):352-62. PubMed ID: 19016478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival.
    Fleischmann A; Schobinger S; Markwalder R; Schumacher M; Burkhard F; Thalmann GN; Studer UE
    Histopathology; 2008 Oct; 53(4):468-75. PubMed ID: 18764879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extranodal extension in lymph node-positive prostate cancer.
    Cheng L; Pisansky TM; Ramnani DM; Leibovich BC; Cheville JC; Slezak J; Bergstralh EJ; Zincke H; Bostwick DG
    Mod Pathol; 2000 Feb; 13(2):113-8. PubMed ID: 10697266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
    J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.
    Briganti A; Capitanio U; Chun FK; Gallina A; Suardi N; Salonia A; Da Pozzo LF; Colombo R; Di Girolamo V; Bertini R; Guazzoni G; Karakiewicz PI; Montorsi F; Rigatti P
    Eur Urol; 2008 Oct; 54(4):794-802. PubMed ID: 18514383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
    Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
    J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting lymph nodes metastasis in prostate cancer through extended vs. standard laparoscopic pelvic lymphadenectomy.
    Arenas LF; Füllhase C; Boemans P; Fichtner J
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S10-4. PubMed ID: 20094944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
    Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
    BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
    Heidenreich A; Varga Z; Von Knobloch R
    J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
    Bader P; Burkhard FC; Markwalder R; Studer UE
    J Urol; 2003 Mar; 169(3):849-54. PubMed ID: 12576797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
    BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in lymph node-positive prostate cancer.
    Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
    Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.
    Briganti A; Karakiewicz PI; Chun FK; Suardi N; Gallina A; Abdollah F; Freschi M; Doglioni C; Rigatti P; Montorsi F
    Int J Urol; 2009 Aug; 16(8):676-81. PubMed ID: 19602006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years.
    Schostak M; Krause H; Miller K; Schrader M; Kempkensteffen C; Kollermann J
    BJU Int; 2007 Jun; 99(6):1409-14. PubMed ID: 17428244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.